PDCD1 and non-small cell lung carcinoma: However, in addition to low objective response rate for some tumors, notably for non–small cell lung carcinoma (NSCLC) and nivolumab8,9, there is a wide inter-individual variability of response to anti-PD-1 therapy, which complicates the task of reliably identifying responders and non-responders.